Oskar Eklund

机构：GlaxoSmithKline (Sweden) · ORCID：0009-0000-8704-5022

发表论文 36 篇 · 总被引 94 次 · h-index 4

代表论文

• Real-world costs of autosomal dominant polycystic kidney disease in the Nordics (2017 · BMC Health Services Research · 被引 28)
• Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial (2023 · Journal of Medical Economics · 被引 15)
• Ecological Benefits of Health Technologies – How to Consider Public Value in Funding Decisions? (2018 · Value in Health · 被引 3)
• EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden (2023 · Value in Health · 被引 1)
• Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study (2026 · The European Journal of Health Economics)
• EE524 Humanistic and Economic Burden of Primary Biliary Cholangitis: A Systematic Review of Health-Related Quality of Life Healthcare Resource Utilization and Associated Cost (2025 · Value in Health)